Lv4
460 积分 2021-02-24 加入
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
9天前
已完结
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
9天前
已完结
US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology A Dangerous Precedent?
1个月前
已完结
Noninferiority Clinical Trials: Overview for the Clinical Cardiologist
1个月前
已完结
淋巴瘤PET/CT及PET/MR显像临床应用指南(2025版)
2个月前
已完结
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera®) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial
3个月前
已完结
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study
5个月前
已完结
A prospective phase 2 study of combination epigenetic therapy against relapsed/refractory peripheral T cell lymphoma
5个月前
已完结
Dual epigenetic therapy plus chemotherapy in peripheral T cell lymphoma with T follicular helper phenotype
5个月前
已完结
Upfront VIP-reinforced-ABVD (VIPrABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma.Results of the randomized phase III trial GOELAMS-LTP95
10个月前
已完结
皖公网安备34019202002308
